PD 0332991 和阿那曲唑治疗 2 期或 3 期雌激素受体阳性和 HER2 阴性乳腺癌
新辅助 PD 0332991(一种细胞周期蛋白依赖性激酶 (Cdk) 4/6 抑制剂)与阿那曲唑联合治疗临床 2 期或 3 期雌激素受体阳性且 HER2 阴性乳腺癌女性的 II 期试验
A Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER+ Human epidermal growth factor receptor 2 (HER2)- breast cancer, to investigate whether the combination of PD 0332991 and anastrozole is able to: 1) improve the pathologic complete response rate when compared to the historical control of single agent aromatase inhibitors, 2) result in fewer patients with on therapy Ki67>10% compared to historical control.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- University of Alabama
-
-
Arizona
-
Scottsdale、Arizona、美国、85259
- Mayo Clinic - Scottsdale
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- Mayo Clinic - Rochester
-
-
Missouri
-
St Louis、Missouri、美国、63122
- Washington University School of Medicine
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Pre-registration PIK3CA Mutant Inclusion
-
Clinical T2-T4c, any N, M0 invasive ER+ (Allred Score of 6-8) and HER2 negative (0 or 1+ by IHC or FISH negative for amplification) breast cancer, by AJCC 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node. Note: Patients with invasive ER+ (Allred Score of 6-8) HER2- breast cancer or DCIS in the contralateral breast the patient are eligible
-
Female ≥18 years of age
-
ECOG performance status of 0, 1 or 2
-
Life expectancy > 4 months
-
Premenopausal, patient must be willing to comply with pregnancy requirements
-
Adequate organ and marrow function
- leukocytes ≥ 3,000/mcL
- absolute neutrophil count ≥ 1,500/mcL
- platelets ≥ 100,000/mcL
- total bilirubin ≤ ULN
- AST(SGOT)/ and ALT(SGPT) < 2.5 X ULN
- Creatinine ≤ ULN
-
Able to understand and willing to sign an IRB-approved written informed consent document
Exclusion
- Prior treatment of this cancer including: surgery, radiation, chemotherapy, biotherapy, hormonal therapy, investigational agent prior to study entry
- Receiving any investigational agents
- Prior therapy with any Cdk4 inhibitor
- Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled symptomatic cardiac arrhythmia, psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant/nursing
- Unwilling to employ adequate contraception
- Known HIV-positive on combination antiretroviral therapy
- Evidence of inflammatory cancer
- Known metastatic disease
- Current use of anticoagulation therapy
- Previous excisional biopsy of the breast cancer or sentinel lymph node biopsy
- Any condition that impairs patient's ability to swallow PD 0332991 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption)
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991 or other agents used in the study
- Corrected QT interval >470 msec
Registration PIK3CA Mutant Inclusion The criteria below must be met in addition to the pre-registration criteria, except treatment with endocrine therapy for this cancer is allowed prior to registration
- PIK3CA mutant cohort: tumor PIK3CA mutation present
- Premenopausal women, serum estradiol level in postmenopausal range ≤ 7 days prior to registration
Exclusion Criteria below must be met in addition to the pre-registration criteria -Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors (i.e. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort)
PIK3CA Wild Type Inclusion
-
Clinical T2-T4c, any N, M0 invasive ER+ (Allred Score of 6-8) and HER2 negative (0 or 1+ by IHC or FISH negative for amplification) breast cancer, by AJCC 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node. Note: Patients with invasive ER+ (Allred Score of 6-8) HER2- breast cancer or DCIS in the contralateral breast the patient are eligible
-
For the PIK3CA wild type cohort: tumor PIK3CA mutation absent. Note that if a patient did not have sufficient research tissue for PIK3CA sequencing at pre-registration or if PIK3CA sequencing result is delayed, she could be registered and enrolled on the PD991 trial without assigning to a particular cohort at the time of enrollment. PIK3CA sequencing will be performed in the future on tumors collected at subsequent time points to assign the treatment cohort or when the PIK3CA sequencing data is available
-
For the endocrine resistant cohort: Ki67 > 10% by central testing at Washington University AMP laboratory from a tumor biopsy performed after at least 2 weeks on neoadjuvant endocrine therapy. Note that prior neoadjuvant endocrine therapy could include any endocrine therapy (including aromatase inhibitor, tamoxifen, fulvestrant) alone or in combination, or endocrine therapy in combination with any investigational agent that is not a Cdk 4/6 inhibitor
*Patients who had a Day 17 Ki67 > 10% from the NCI9170 trial are eligible for the endocrine resistant cohort
-
Female >18 years of age
-
ECOG performance status of 0, 1 or 2
-
Life expectancy > 4 months
-
If premenopausal, patient must be willing to comply with pregnancy requirements
-
Adequate organ and marrow function:
- leukocytes ≥ 3,000/mcL
- absolute neutrophil count ≥ 1,500/mcL
- platelets ≥ 100,000/mcL
- total bilirubin ≤ ULN
- AST(SGOT)/ and ALT(SGPT) < 2.5 X ULN
- Creatinine ≤ ULN
-
In premenopausal women, serum estradiol level in postmenopausal range ≤ 7 days prior to registration.
-
Able to understand and willing to sign an IRB-approved written informed consent document
Exclusion
- Prior treatment of this cancer including: Surgery, Radiation therapy, Chemotherapy, Biotherapy, Hormonal therapy, Investigational agent prior to study entry
- Receiving any other investigational agents
- Prior therapy with any Cdk4 inhibitor
- Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled symptomatic cardiac arrhythmia, psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant/nursing
- Unwilling to employ adequate contraception
- Known HIV-positive on combination antiretroviral therapy
- Evidence of inflammatory cancer
- Known metastatic disease
- Current use of anticoagulation therapy
- Previous excisional biopsy of the breast cancer or sentinel lymph node biopsy
- Any condition that impairs patient's ability to swallow PD 0332991 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption)
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991 or other agents used in the study
- Corrected QT interval >470 msec
- Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors (i.e. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort)
Endocrine Resistant Inclusion
-
Clinical T2-T4c at diagnosis or screening, any N, M0 invasive ER+ (Allred Score at least 3 or > 1% ER positivity) and HER2 negative (0 or 1+ by IHC or FISH negative or equivocal) breast cancer, by AJCC 7th edition clinical staging, with the goal being surgery to completely excise the tumor in the breast and the lymph node. Note: Patients with invasive breast cancer that is ER pos, HER2 neg or equivocal or DCIS in the contralateral breast are eligible; multi-focal diseases are not excluded. The dominant lesion will be followed per protocol
-
Ki67 > 10% by central testing at Washington University AMP laboratory from a tumor biopsy performed after at least 2 weeks on neoadjuvant endocrine therapy. If Ki67 is > 10% by local testing, the Ki67 slide and H&E slide need to be reviewed by the study pathologist to confirm eligibility (discuss with Study Chair). For patients external to Washington University, please contact the Washington University coordinator by email so that a screening ID# can be assigned prior to shipment of the slides
-
Female ≥ 18 years of age
-
ECOG performance status of 0, 1 or 2
-
Pre- or post-menopausal women are eligible. If premenopausal, patient must be willing to comply with pregnancy requirements and agrees with GnRH agonist therapy for ovarian suppression during the study
-
Adequate organ and marrow function:
- Leukocytes ≥ 3,000/mcL
- Absolute neutrophil count ≥ 1,500/mcL
- Platelets ≥ 100,000/mcL
- Total bilirubin ≤ ULN
- AST(SGOT)/ and ALT(SGPT) < 2.5 X ULN
- Creatinine ≤ ULN
-
Able to understand and willing to sign an IRB-approved written informed consent document
Exclusion
- Prior treatment of this cancer including: Surgery, Radiation, Chemotherapy
- Receiving any other investigational agents
- Prior therapy with Cdk4 inhibitor
- Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled symptomatic cardiac arrhythmia, psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant/nursing
- Unwilling to employ adequate contraception
- Known HIV-positive on combination antiretroviral therapy
- Known metastatic disease
- Current use of anticoagulation therapy
- Previous excisional biopsy of the breast cancer or sentinel lymph node biopsy
- Any condition that impairs patient's ability to swallow PD 0332991 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption)
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991 or other agents used in the study
- Corrected QT interval >470 msec
- Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors (i.e. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort)
Adjuvant Inclusion
-
Derived benefit from PD 0332991 in the neoadjuvant setting in this trial. This includes the 26 patients who achieved complete cell cycle arrest only after the addition of PD 0332991 (C1D1 Ki67 >2.7% and C1D15 Ki67 ≤ 2.7%) from the main study (PIK3CA WT, mutant, or unknown cohorts) as well as any patients who have a Ki67 ≤ 10% on C1D15 biopsy in the endocrine resistant cohort
-
ECOG performance status of 0, 1 or 2
-
Premenopausal, patient must be willing to comply with pregnancy requirements laid out
-
Adequate organ and marrow function
- leukocytes ≥ 3,000/mcL
- absolute neutrophil count ≥ 1,500/mcL
- platelets ≥ 100,000/mcL
- total bilirubin ≤ ULN
- AST(SGOT)/ and ALT(SGPT) ≤ 2.5 X ULN
- Creatinine ≤ ULN
-
Underwent surgery of the breast and axilla for curative intent
-
At least 4 weeks post completion of adjuvant chemotherapy and radiation therapy if indicated
-
Patients who already started on adjuvant hormonal therapy are eligible under the following conditions:
- For the 26 patients who enrolled in the initial cohorts and derived benefit from neoadjuvant PD 0332991 (C1D1 Ki67 >2.7% and C1D15 Ki67 ≤ 2.7%), adjuvant PD 0332991 should be initiated as soon as possible if adjuvant hormonal therapy has been initiated and the patient has completed radiation if indicated
- For patients who enrolled in the endocrine resistant cohort and derived benefit from neoadjuvant PD 0332991 (C1D15 Ki67 ≤ 10%), adjuvant PD 0332991 should be initiated within 6 months or sooner after initation of adjuvant hormonal therapy
-
Able to understand and willing to sign an IRB-approved written informed consent document
Exclusion
- Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled symptomatic cardiac arrhythmia, ssychiatric illness/social situations that would limit compliance with study requirements
- Pregnant/nursing
- Unwilling to employ adequate contraception
- Known HIV-positive on combination antiretroviral therapy. -Known metastatic disease
- Any condition that impairs patient's ability to swallow PD 0332991 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption)
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991 or other agents used in the study
- Corrected QT interval >470 msec
- Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors (i.e. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm 1: PIK3CA Wild Type Cohort
|
其他名称:
其他名称:
-Breast and axillary lymph node surgery |
|
实验性的:Arm 2: PIK3CA Mutant Type Cohort
|
其他名称:
其他名称:
-Breast and axillary lymph node surgery |
|
实验性的:Arm 3: Endocrine Resistant Cohort
|
其他名称:
其他名称:
-Breast and axillary lymph node surgery |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Complete Cell Cycle Arrest at Cycle 1 Day 15 (PIK3CA Wild Type Cohort Only)
大体时间:At cycle 1 day 15 (2 weeks)
|
Complete cell cycle arrest is defined as Ki67 ≤ 2.7% following 2 weeks of neoadjuvant PD 0332991 |
At cycle 1 day 15 (2 weeks)
|
|
Number of Participants With Complete Cell Cycle Arrest at Cycle 1 Day 15 (Endocrine Resistant Cohort Only)
大体时间:At cycle 1 day 15 (2 weeks)
|
Complete cell cycle arrest is defined as Ki67 ≤ 2.7% following 2 weeks of neoadjuvant PD 0332991 |
At cycle 1 day 15 (2 weeks)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
总生存期
大体时间:5年
|
5年
|
|
|
无复发生存率
大体时间:5年
|
5年
|
|
|
Number of Participants With Complete Cell Cycle Arrest at Cycle 1 Day 15 ( PIK3CA Mutant Type Cohort Only)
大体时间:At cycle 1 day 15 (2 weeks)
|
Complete cell cycle arrest is defined as Ki67 ≤ 2.7% following 2 weeks of neoadjuvant PD 0332991 |
At cycle 1 day 15 (2 weeks)
|
|
Number of Participants With Complete Cell Cycle Arrest
大体时间:Cycle 1 day 1 and cycle 1 day 15 (2 weeks)
|
Compare rate of complete cell cycle arrest (defined as Ki67 ≤ 2.7%) arrest between C1D1 and C1D15 |
Cycle 1 day 1 and cycle 1 day 15 (2 weeks)
|
|
Clinical Response Rate
大体时间:16 weeks
|
|
16 weeks
|
|
Radiologic Response Rate
大体时间:At the end of cycle 4 prior to surgery (estimated to be 16 weeks)
|
|
At the end of cycle 4 prior to surgery (estimated to be 16 weeks)
|
|
Safety of PD 0332991 in Combination in Anastrozole as Measured by Frequency and Grade of Related Adverse Events
大体时间:From start of treatment through 30 days after completion of an estimated 4 months of neoadjuvant therapy
|
The maximum grade for each type of adverse event will be recorded for each patient using the NCI-CTCAE v4.0 coding scheme, and frequency tables will be reviewed to determine patterns. Additionally, the relationship (possibly related, probably related, and definitely related) of the adverse event(s) to the study treatment will be taken into consideration. |
From start of treatment through 30 days after completion of an estimated 4 months of neoadjuvant therapy
|
|
Number of Participants With a PEPI-0 Score
大体时间:At the time of surgery (estimated to be 5 months)
|
|
At the time of surgery (estimated to be 5 months)
|
|
Change in Ki67 Level of Tumor Specimens
大体时间:Pre-treatment and cycle 1 day 15
|
To assess Ki67 level on serially collected tumor specimens |
Pre-treatment and cycle 1 day 15
|
|
Change in Ki67 Level of Tumor Specimens
大体时间:Cycle 1 day 15 and at time of surgery (approximately 2-4 weeks post completion of cycle 4 - each cycle is 28 days)
|
To assess Ki67 level on serially collected tumor specimens |
Cycle 1 day 15 and at time of surgery (approximately 2-4 weeks post completion of cycle 4 - each cycle is 28 days)
|
|
Number of Participants With Pathologic Complete Response (pCR)
大体时间:At the time of surgery (estimated to be 5 months)
|
-A pathologic complete response is defined as no histology evidence of invasive tumor cells in the surgical breast specimen and sentinel or axillary lymph nodes. |
At the time of surgery (estimated to be 5 months)
|
|
Safety Profile of Study Therapy During Adjuvant Therapy as Measured by Frequency and Grade of Adverse Event
大体时间:From start of adjuvant therapy through 30 days after completion of adjuvant therapy (estimated to be 2 years)
|
The maximum grade for each type of adverse event will be recorded for each patient using the NCI-CTCAE v4.0 coding scheme, and frequency tables will be reviewed to determine patterns. Additionally, the relationship (possibly related, probably related, and definitely related) of the adverse event(s) to the study treatment will be taken into consideration. |
From start of adjuvant therapy through 30 days after completion of adjuvant therapy (estimated to be 2 years)
|
|
Local Recurrence Rate
大体时间:5 years
|
Local recurrence is defined as histologic evidence of ductal carcinoma in situ or invasive breast cancer in the ipsilateral breast or chest wall. |
5 years
|
|
Regional Recurrence Rate
大体时间:5 years
|
Regional recurrence is defined as the cytologic or histologic evidence of disease in the ipsilateral internal mammary, ipsilateral supraclavicular, ipsilateral infraclavicular and/or ipsilateral axillary nodes or soft tissue of the ipsilateral axilla. |
5 years
|
|
Distant Recurrence Rate
大体时间:5 years
|
Distant recurrence is defined as the cytologic, histologic, and/or radiographic evidence of disease in the skin, subcutaneous tissue, lymph nodes (other than local or regional metastasis), lung, bone narrow, central nervous system or histologic and/or radiographic evidence of skeletal or liver metastasis. |
5 years
|
|
Rate of Second Primary Breast Cancer
大体时间:5 years
|
Second primary breast cancer is defined histologic evidence of ductal carcinoma in situ or invasive breast cancer in the contralateral breast or chest wall. |
5 years
|
|
Rate of Second Primary Cancer (Non-breast)
大体时间:5 years
|
Second primary cancer (non-breast) is defined as any non-breast second primary cancer other than squamous or basal cell carcinoma of the skin, melanoma in situ, or carcinoma in situ of the cervix is to be reported and should be confirmed histologically whenever possible. |
5 years
|
合作者和调查者
合作者
调查人员
- 首席研究员:Cynthia X Ma, M.D., Ph.D.、Washington University School of Medicine
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 201301106
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.